1. Catalog
  2. IGCS 2022 Master Session: Ovarian Cancer
Image For Activity Cover
IGCS 2022 Master Session: Ovarian Cancer
Description
Held on Septener 30, 2022 at the IGCS 2022 Annual Global Meeting in New York City, USA. This session is dedicated to innovations in ovarian cancer biology, surgery and treatment. Speakers in this session will cover the role of “biology” in clinical outcomes and potential for surgical decision making, timing and new approaches. With the growing interest in intraoperative treatments, a critical appraisal of HIPEC will be performed. The second part will discuss current and emerging systemic therapies in the first-line setting and how the ongoing trials may change clinical practice. Next, several “hot topics” in ovarian cancer will be presented, including the mechanisms of resistance to PARP inhibitors, front-line maintenance therapy as part of standard-of-care (SOC) for at least 50% of women with ovarian cancer and the new and very promising developmental therapies. To close this session dedicated to ovarian cancer, a debate on the role of surgery for relapsed disease from the US and European perspectives will be debated. 

Master Session: Ovarian Cancer

Chair(s)

Andreas Du Bois (Germany)
Thomas J. Herzog (USA)
Amit Oza (Canada)
Isabella L. Ray-Coquard (France)
Anil K. Sood (USA) 

DEBATE 1: SHARPENING THE SCALPEL WITH MOLECULAR BIOLOGY

Moderated by Andreas Du Bois

Debate 1: Pro

Anil K. Sood (USA)

Debate 1: Con

Florian Heitz (Germany) 

PANEL 1: POTENTIAL IMPACT ON STANDARD OF CARE: REVIEW OF PENDING TRIALS

Moderated by Amit Oza

Potential impact on standard of care: Review of pending trials - Overview

Isabella L. Ray-Coquard (France)

Potential impact on standard of care: Review of pending trials - Analysis

Bradley J. Monk (USA)

PANEL 2: DEVELOPMENTAL THERAPEUTICS 

Moderated by Isabelle Ray-Coquard (France)

Overcoming PARP resistance

Amit Oza (Canada) 

Leveraging new pathways for ovarian cancer

Shannon N. Westin (USA)

PANEL 3: Current level of evidence supporting HIPEC in clinical care

Moderated by Anil Sood (USA)

HIPEC: A Critical Appraisal of Promises and Challenges

Kathleen N. Moore (USA) 

Is it ready for primetime? Addressing the knowledge gaps in HIPEC data

Thomas J. Herzog (USA) 

DEBATE 2: SECONDARY CYTOREDUCTION

Moderated by Thomas Herzog (USA)

Debate 2: Pro

Andreas Du Bois (Germany)

Debate 2: Con

Robert L. Coleman (USA)
Summary
Availability: On-Demand
Cost: FREE
Create Account
Recommended
Contact education@igcs.org for assistance.
Powered By